Sunshine Biopharma IncNASDAQ:SBFM
- LAST PRICE2.9753
- TODAY'S CHANGE (%)0.0453 (1.5461%)
- Bid / Lots2.9100/ 5
- Ask / Lots3.0100/ 2
- Open / Previous Close2.9200 / 2.9300
- Day Range
- 52 Week Range
- Volume46,182
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SBFM |
|---|---|---|
| 09:32 ET | 325 | 2.92 |
| 09:39 ET | 100 | 2.95 |
| 09:43 ET | 1000 | 2.91 |
| 09:48 ET | 1100 | 2.96 |
| 09:52 ET | 425 | 2.93 |
| 09:54 ET | 1500 | 2.93 |
| 09:57 ET | 100 | 2.99 |
| 10:01 ET | 400 | 2.94 |
| 10:10 ET | 927 | 2.99 |
| 10:12 ET | 2100 | 2.9279 |
| 10:14 ET | 300 | 2.9467 |
| 10:21 ET | 2000 | 2.95 |
| 10:30 ET | 1000 | 2.93 |
| 10:46 ET | 5100 | 2.93 |
| 10:48 ET | 150 | 2.9301 |
| 10:51 ET | 1200 | 2.93 |
| 11:11 ET | 223 | 2.964 |
| 11:13 ET | 1414 | 2.9408 |
| 11:26 ET | 310 | 2.96 |
| 11:31 ET | 400 | 2.9408 |
| 11:44 ET | 300 | 2.9404 |
| 11:47 ET | 500 | 2.948 |
| 12:00 ET | 103 | 2.96 |
| 12:02 ET | 100 | 2.94 |
| 12:07 ET | 120 | 2.9401 |
| 12:30 ET | 135 | 2.9401 |
| 12:32 ET | 1100 | 2.97 |
| 12:34 ET | 300 | 2.9765 |
| 12:38 ET | 6352 | 2.97 |
| 12:39 ET | 350 | 3.0397 |
| 12:43 ET | 135 | 3 |
| 12:52 ET | 300 | 3.05 |
| 12:54 ET | 2300 | 2.9887 |
| 01:14 ET | 126 | 2.9753 |
| 01:42 ET | 100 | 2.96 |
| 02:09 ET | 145 | 2.9592 |
| 02:11 ET | 100 | 3.0018 |
| 02:13 ET | 1001 | 3.01 |
| 02:44 ET | 300 | 2.985 |
| 02:58 ET | 166 | 3.0099 |
| 03:16 ET | 3956 | 2.95 |
| 03:43 ET | 1500 | 2.9447 |
| 03:56 ET | 200 | 2.94 |
| 03:57 ET | 539 | 2.96 |
| 03:59 ET | 1719 | 2.9753 |
Sep 26, 2024
Sunshine Biopharma Launches Two New Generic Prescription Drugs, from 10:12AM ET on Thursday Sep 26, 2024 by Dow Jones
10:12AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 4, 2024
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth, from 9:15AM ET on Wednesday Sep 04, 2024 by Dow Jones
9:15AM ET on Wednesday Sep 04, 2024 by Dow JonesGlobal Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031, from 8:30AM ET on Wednesday Sep 04, 2024 by Dow Jones
8:30AM ET on Wednesday Sep 04, 2024 by Dow JonesSunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry, from 8:03AM ET on Wednesday Sep 04, 2024 by Dow Jones
8:03AM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sunshine Biopharma Inc | 3.3M | 0.0x | --- |
cbdMD Inc | 1.7M | 0.0x | --- |
Cyanotech Corp | 5.5M | -0.9x | --- |
Gelesis Holdings Inc | 70.0 | 0.0x | --- |
Synovics Pharmaceuticals Inc | 3.0K | 0.0x | --- |
Neurobiological Technologies Inc | 2.7K | 0.0x | --- |
Company Information
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
Contact Information
- Headquarters
- 333 Las Olas Way, Cu4 Suite 433FORT LAUDERDALE, FL, United States 33301
- Phone
- 954-515-0810
- Fax
- 514-426-6101
Executives
- Chairman of the Board, President, Chief Executive Officer
- Steve Slilaty
- Chief Financial Officer, Secretary
- Camille Sebaaly
- Chief Operating Officer
- Marc Beaudoin
- Chief Science Officer, Director
- Abderrazzak Merzouki
- Chief Development Officer
- Malek Chamoun
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3M |
|---|---|
Revenue (TTM) | $30.5M |
Shares Outstanding | 1.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.04 |
EPS | $-194.01 |
Book Value | $1,513.73 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
